Article
Immunology
Motoi Yamashita, Shiori Eguchi, Dan Tomomasa, Takahiro Kamiya, Daiki Niizato, Noriko Mitsuiki, Takeshi Isoda, Hanako Funakoshi, Yuki Mizuno, Kentaro Okamoto, Tuan Minh Nguyen, Hidetoshi Takada, Masatoshi Takagi, Kohsuke Imai, Tomohiro Morio, Hirokazu Kanegane
Summary: Leukocyte adhesion deficiency type I (LAD-I) is a rare genetic immune disorder that can be cured with allogeneic hematopoietic cell transplant (HCT). In cases where ideal donors are unavailable, HLA-haploidentical HCT with posttransplant cyclophosphamide (PT-CY) can be a safe and effective alternative.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus, Christopher G. Kanakry
Summary: Post-transplantation cyclophosphamide (PTCy) is a drug used to treat graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT). It works by impairing and suppressing antigen-specific T cells. In this study, reduced proliferation of CD4(+) T cells at day +7 and preferential recovery of CD4(+)CD25(+)Foxp3(+) regulatory T cells (T-regs) at day +21 were identified as potential biomarkers associated with optimal PTCy dosing and timing.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Javier Martinez-Sanz, Jorge Diaz-alvarez, Marta Rosas, Raquel Ron, Jose Antonio Iribarren, Enrique Bernal, Felix Gutierrez, Andres Ruiz Sancho, Noemi Cabello, Julian Olalla, Santiago Moreno, Sergio Serrano-Villar
Summary: The study suggests that a low CD4/CD8 ratio during HIV treatment is associated with immunosenescence. Data analysis shows that patients with a CD4/CD8 ratio less than 0.3 in the second year of ART have an increased risk of developing SNAEs in the next five years.
Article
Oncology
Hengwei Wu, Zhen Cai, Jimin Shi, Yi Luo, He Huang, Yanmin Zhao
Summary: The loss of patient-specific HLA after haploidentical hematopoietic stem cell transplantation is considered a relapse mechanism affecting graft-versus-leukemia (GVL) effects. Blinatumomab showed promising results in treating patients with HLA loss relapse, with most patients achieving complete remission or partial recovery within the first treatment cycle and meeting the primary endpoint within 2 cycles. Adverse effects included cytokine release syndrome, cytopenias, and elevated liver enzymes. Further studies are needed to assess the efficacy of blinatumomab in this patient population.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Biophysics
Michael H. Albert, Mehtap Sirin, Manfred Hoenig, Fabian Hauck, Catharina Schuetz, Rajat Bhattacharyya, Polina Stepensky, Elad Jacoby, Tayfun Gungor, Rita Beier, Ansgar Schulz
Summary: The study found that a post-transplantation cyclophosphamide-based HLA-haploidentical salvage HSCT after irradiation-free conditioning resulted in excellent engraftment and overall survival in children with non-malignant diseases.
BONE MARROW TRANSPLANTATION
(2021)
Article
Cell & Tissue Engineering
Ying Yang, Ming Zhang, Mengqi Li, Yingchun Li, Wei Yang, Zhuogang Liu, Hongtao Wang
Summary: This study found that adding an unrelated umbilical cord blood unit to haploidentical hematopoietic stem cell transplantation can improve the prognosis and enhance the graft versus leukemia effect without increasing the incidence of graft versus host disease.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Cell & Tissue Engineering
Xueer Xu, Cheng Zu, Mingming Zhang, Pingnan Xiao, Ruimin Hong, Jingjing Feng, Huijun Xu, Jiazhen Cui, Jian Yu, Jimin Shi, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu
Summary: This study reported on a patient with refractory hepatosplenic & gamma;& delta; T-cell lymphoma who achieved complete remission and maintained it after receiving HLA fully-mismatched sibling-derived CD7 CAR-T therapy followed by haploidentical hematopoietic stem cell transplantation. This is the first case of its kind, highlighting the potential of CAR-T therapy and haploidentical HSCT in treating relapsed/refractory T-cell lymphoma.
CELL TRANSPLANTATION
(2023)
Article
Biotechnology & Applied Microbiology
Chiara M. M. Cattaneo, Thomas Battaglia, Jos Urbanus, Ziva Moravec, Rhianne Voogd, Rosa de Groot, Koen J. J. Hartemink, John B. A. G. Haanen, Emile E. E. Voest, Ton N. N. Schumacher, Wouter Scheper
Summary: A genetic neoantigen screening system is developed to identify CD4(+) and CD8(+) T cell-recognized neoantigens across patients' complete HLA genotypes.
NATURE BIOTECHNOLOGY
(2023)
Article
Biophysics
Fei-Fei Tang, Xiang-Yu Zhao, Ming-Rui Huo, Ying-Jun Chang, Wei Han, Yu-Hong Chen, Chen-Hua Yan, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yu Wang
Summary: This study found that NIMA mismatch was associated with better survival outcomes, and donor age and sex did not seem to influence haploidentical hematopoietic stem cell transplantation.
BONE MARROW TRANSPLANTATION
(2021)
Article
Infectious Diseases
Alice Zhabokritsky, Leah Szadkowski, Curtis Cooper, Mona Loutfy, Alexander Wong, Alison McClean, Robert S. Hogg, Sharon L. Walmsley
Summary: The study found that early initiation of ART and having a higher baseline CD4+ T-cell count are associated with achieving CD4:CD8 ratio normalization. The type of ART class used did not impact the normalization of the ratio when adjusting for baseline characteristics.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Cell Biology
Vanesa Garrido-Rodriguez, Ines Herrero-Fernandez, Maria Jose Castro, Ana Castillo, Isaac Rosado-Sanchez, Maria Isabel Galva, Raquel Ramos, Israel Olivas-Martinez, Angel Bulnes-Ramos, Julio Canizares, Manuel Leal, Yolanda Maria Pacheco
Summary: The CD4/CD8 T-cell ratio is a useful marker for evaluating immune features in older individuals, showing differences in thymic output and immune profiles that can affect health status.
Article
Oncology
Sebastian Johannes Schober, Erika Hallmen, Florian Ressle, Hendrik Gassmann, Carolin Prexler, Angela Wawer, Irene von Luettichau, Ruth Ladenstein, Bernarda Kazanowska, Gustaf Ljungman, Felix Niggli, Olli Lohi, Julia Hauer, Bernd Gruhn, Thomas Klingebiel, Peter Bader, Stefan Burdach, Peter Lang, Monika Sparber-Sauer, Ewa Koscielniak, Uwe Thiel
Summary: In this retrospective analysis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) did not show a significant survival advantage compared to standard-of-care regimens in patients with stage IV alveolar rhabdomyosarcoma (RMA). Individualized treatment strategies and disease status are important factors in determining patient survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Cristina Bottino, Mariella Della Chiesa, Stefania Sorrentino, Martina Morini, Chiara Vitale, Alessandra Dondero, Annalisa Tondo, Massimo Conte, Alberto Garaventa, Roberta Castriconi
Summary: Despite the current treatment for high-risk neuroblastomas (HR-NB), the 5-year overall survival rate remains low. There is a need to improve the standard therapeutic protocol, particularly in enhancing the immune response against the tumor.
Article
Hematology
Naoki Kurita, Tatsuhiro Sakamoto, Takayasu Kato, Manabu Kusakabe, Yasuhisa Yokoyama, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba
Summary: Cytokine release syndrome (CRS) is common in HLA-haploidentical hematopoietic stem-cell transplantations, but initiating cyclophosphamide along with cyclosporine and mycophenolate mofetil can reduce CRS without increasing the risk of graft-versus-host disease (GVHD). The study showed a high disease-free survival rate at day 100 and a moderate overall survival rate at 3 years.
ANNALS OF HEMATOLOGY
(2021)
Article
Biophysics
Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, Benedetto Bruno, Alessandro Rambaldi, Pietro Pioltelli, Giorgio La Nasa, Gerard Socie, Stephan Mielke, Marco Ruggeri, Riccardo Saccardi, Georg-Nikolaus Franke, Juergen Finke, Bipin N. Savani, Annalisa Ruggeri, Mohamad Mohty
Summary: The study showed that allo-HCT from >= 2 HLA allele MMUD in acute leukemia patients resulted in acceptable leukemia-free survival and refined GVHD-free, relapse-free survival, although HLA-DR mismatch was identified as a poor prognostic factor.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Li-Ping Yang, Peng Zhao, Ye-Jun Wu, Hai-Xia Fu, Yun He, Xiao-Dong Mo, Meng Lv, Feng-Rong Wang, Chen-Hua Yan, Yu-Hong Chen, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
Summary: This study evaluated the efficacy and outcomes of therapeutic plasma exchange (TPE) for patients with transplant-associated thrombotic microangiopathy (TA-TMA). The results showed that TPE had a positive response in TA-TMA patients without gastrointestinal bleeding, and a higher volume of TPE was associated with better outcomes.
BONE MARROW TRANSPLANTATION
(2022)
Article
Medicine, Research & Experimental
Xing-Xing Yu, Qian-Nan Shang, Xue-Fei Liu, Mei He, Xu-Ying Pei, Xiao-Dong Mo, Meng Lv, Ting-Ting Han, Ming-Rui Huo, Xiao-Su Zhao, Ying-Jun Chang, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiang-Yu Zhao, Xiao-Jun Huang
Summary: Donor NKG2C homozygosity contributes to CMV clearance by promoting the quantitative and qualitative reconstruction of adaptive NKG2C+ NK cells after haploidentical allo-HSCT.
Review
Oncology
Zhi-Ling Yan, Yue-Wen Wang, Ying-Jun Chang
Summary: This article summarizes the recent advances and challenges in cellular immunotherapies for multiple myeloma (MM), including autologous stem cell transplantation, allogeneic stem cell transplantation, and CAR T-cell approaches. It also discusses future directions and proposes a specific algorithm for cellular therapies for MM and the probability of minimal residual disease-directed therapy.
ONCOLOGY AND THERAPY
(2022)
Article
Immunology
Huidong Guo, Ming Wang, Bixia Wang, Liping Guo, Yifei Cheng, Zhidong Wang, Yu-Qian Sun, Yu Wang, Ying-Jun Chang, Xiao-Jun Huang
Summary: PRDM1 is a master regulator in inducing human primary T cell hyporesponsiveness by directly or indirectly regulating a series of key genes that are involved in T cell function and activation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Dao-Xing Deng, Shuang Fan, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xu-Ying Pei, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The immune reconstitution in patients who recovered from steroid-refractory acute graft-versus-host disease (SR-aGVHD) after basiliximab treatment was observed. The study showed that the recovery was fastest for monocytes and CD8(+) T cells, followed by lymphocytes, CD3(+) T cells, and CD19(+) B cells, and slowest for CD4(+) T cells. The recovery of immune cell subsets was comparable between different doses of basiliximab. The results suggest that basiliximab may not have a negative impact on immune reconstitution in patients with SR-aGVHD.
FRONTIERS IN ONCOLOGY
(2022)
Letter
Biophysics
Lanping Xu, Yue Lu, Jing Chen, Shuwen Sun, Shaoyan Hu, Shunqing Wang, Xuedong Wu, Yuan Sun, Dingming Wan, Yajing Xu, Hui Jiang, Chunfu Li, Mei Lan, Erlie Jiang, Fei Li, Sixi Liu, Yongmin Tang, Fan Lin, Peihua Lu, Chengjuan Luo, Xiaojun Huang
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Cuiyan Zhou, Fengmei Zheng, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Yuewen Wang, Xiaodong Mo, Yifei Cheng, Yuhong Chen, Meng Lv, Fengrong Wang, Chenhua Yan, Wei Han, Huan Chen, Lanping Xu, Yu Wang, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang, Yingjun Chang
Summary: CD34(+) cell dose has an impact on hematopoietic recovery in ALL patients, especially in pre-HSCT MRD-positive patients, where higher CD34(+) cell doses are associated with faster neutrophil and platelet engraftment. However, we did not observe direct correlations between CD34(+) cell dose and relapse, TRM, LFS, or OS.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Biology
Qi Wen, Zheng-Li Xu, Yu Wang, Meng Lv, Yang Song, Zhong-Shi Lyv, Tong Xing, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong
Summary: This study found that glycolysis plays a critical role in T cell activation and induction of human aGvHD. Regulating glycolysis offers a potential pathogenesis-oriented therapeutic strategy for aGvHD patients, and the combination of GCs and glycolysis inhibitors may be a novel first-line combination therapy for aGvHD patients.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Article
Hematology
Ting Huang, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: This study compared the clinical outcomes of AML patients with and without TP53 mutations who underwent haplo-HSCT, and found no significant differences in 2-year clinical outcomes between the two groups. Multivariable analysis also showed that TP53 mutations had no significant impact on relapse rate, mortality rate, overall survival, graft-versus-host disease, leukemia-free survival or GvHD-free/relapse-free survival. The findings suggest that patients with AML with TP53 mutations may at least partially benefit from haplo-HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Xin-Xin Liu, Xin-An Pan, Meng-Ge Gao, Jun Kong, Hao Jiang, Ying-Jun Chang, Xiao-Hui Zhang, Yu Wang, Kai-Yan Liu, Zhong Chen, Xiao-Su Zhao, Xiao-Jun Huang
Summary: This study found that EVI1 high expression was associated with poor prognosis in the Non-KMT2A-MLLT3 group and both KMT2A-MLLT3 and Non-KMT2A-MLLT3 patients who received chemotherapy alone had poorer prognosis than those who received allogeneic hematopoietic stem cell transplant. High EVI1 expression was shown to have an adverse effect on AML with KMT2A rearrangement in different risk stratification subtypes.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Virology
Li-Ping Shui, Yan Zhu, Xiao-Qin Duan, Yu-Ting Chen, Li Yang, Xiao-Qiong Tang, Hong-Bin Zhang, Qing Xiao, Li Wang, Lin Liu, Xiao-Hua Luo
Summary: The patterns of hepatitis B virus reactivation (HBV-R) in HBsAg (-)/HBcAb (+) patients with B-cell non-Hodgkin lymphoma (NHL) receiving rituximab based immunochemotherapy have not been well described. The study found a high incidence of HBV-R and high mortality after HBV-R in HBsAg (-)/HBcAb (+)/HBeAg (-)/HBeAb (+) patients with B-cell NHL, suggesting the need for prophylactic antiviral therapy.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Xiao-Hua Luo, Thomas Poiret, Zhenjiang Liu, Qingda Meng, Anurupa Nagchowdhury, Per Ljungman
Summary: In allogeneic hematopoietic cell transplantation, reconstitution of virus-specific T cells and leukemia-specific T cells is crucial for patient protection. Cytomegalovirus (CMV) infection is a significant cause of morbidity and mortality after transplantation. Recent data suggests that CMV reactivation is associated with a reduced risk of leukemia relapse in AML patients. Our study found that CMV-specific CD8+ T cells reconstituted faster than WT1-specific CD8+ T cells. Furthermore, CMV-specific T cells exhibited lower exhaustion markers and higher functionality compared to WT1-specific T cells. Notably, patients with CMV reactivation had a higher frequency of CMV-specific T cells and different expression patterns of Eomes and T-bet compared to patients without CMV reactivation. The kinetics of CMV-specific and WT1-specific T cell reconstitution may be associated with measurable residual disease and leukemia relapse. These findings suggest that CMV reactivation may influence WT1-specific T cell reconstitution after allo-HSCT, potentially affecting the remission/relapse of AML.
FRONTIERS IN IMMUNOLOGY
(2023)
Meeting Abstract
Biophysics
D. -X. Deng, S. Fan, M. -Z. Shen, X. -H. Zhang, L. -P. Xu, Y. Wang, C. -H. Yan, H. Chen, Y. -H. Chen, W. Han, F. -R. Wang, J. -Z. Wang, K. -Y. Liu, X. -J. Huang, X. -D. Mo
BONE MARROW TRANSPLANTATION
(2022)
